EMBC
Embecta Corp.
Healthcare — Medical Instruments & Supplies
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
None
2 analysts
$5.79
+$0.13 (+2.30%)
Target:
$4.00
(-30.9%)
Price History
52-Week Range
Sign in to add EMBC to a watchlist or set price alerts.
Fundamentals
| Market Cap | $199.34M |
| P/E Ratio (TTM) | 1.78 |
| Forward P/E | 1.93 |
| EPS (TTM) | $1.89 |
| Dividend Yield | 13.67% |
| Profit Margin | 10.73% |
| Revenue Growth | -14.40% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $4.00 |
| Analysts | 2 |
| Next Earnings | Aug 7, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 56.4 |
| Beta | 0.81 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $15.55 |
| 52-Week Low | $2.77 |
| 50-Day Avg | $4.45 |
| 200-Day Avg | $9.98 |
| Avg Volume | $2.39M |
| Volume | $2.02M |
Performance Analysis
NEUTRALEMBC presents a mixed picture with both positive and negative indicators.
~
Trading at 24% of its 52-week range.
+
RSI at 56.4 shows positive momentum.
+
P/E of 1.8 suggests the stock may be undervalued.
-
Revenue declined 14.4% year-over-year.
~
Wall Street consensus is "none" from 2 analysts.
-
Average analyst target of $4.00 implies 30.9% downside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:07 UTC
Back to Screener Export Report